Ultragenyx Pharmaceutical Inc SETRUSUMAB Phase 2 Data Conference Call Transcript
Good afternoon, and welcome to the UX143 Phase II Data Conference Call. (Operator Instructions)
It is now my pleasure to turn the call over to Joshua Higa, Vice President and Head of Investor Relations.
Thank you. Earlier today, we issued a press release and updated slides in our corporate deck that outlined the positive results from the Phase II Orbit study in osteogenesis imperfecta, both of which you can find on our website at ultragenyx.com.
Joining me today are Emil Kakkis, Chief Executive Officer and President; and Eric Crombez, Chief Medical Officer.
I'd like to remind everyone that during today's call, we'll be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
